Follow The Filings

VCYT Veracyte Inc.

Health Care, filed as VERACYTE INC (COM), Equity As of 2026 Q3 so far: 135 of 140 managers we track have filed Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q3

  • 2 Owners
  • Max 0.8%
  • $166M
  • 1 add 1 small

In 2026 Q3 Cathie Wood added to Veracyte.

Who owns this now

Largest portfolio weights among holders, up to 0.8% (Cathie Wood, ARK Investment Management). Not free-float ownership.

  1. Cathie Wood Add 0.79%
  2. Ron Baron Add 0.05%

Who owns VCYT

Sorted by value, long equity only, as of 2026 Q3.

History
Cathie Wood, ARK Investment Management 0.79% Add +29.1% 2,964,650 $136M History
Ron Baron, BAMCO Inc. (Baron Capital) 0.05% Small add 0.0% 650,895 $30M History

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by VCYT's executives, directors and 10% owners in the last 12 months, from their Form 4s

All VCYT insider trades
  • None no insider bought on the open market
  • $1.1M sold by 1 insider outside a trading plan
  • $17.7M sold by 10 insiders under 10b5-1 plans
  1. Jens Holstein Director
    Planned sale
    $728K 15,000 shares at $48.50 35% of stake
    Traded Sep 24–Oct 27 Filed Oct 28
  2. Karin Eastham Director
    Planned sale
    $743K 14,850 shares at $50.00 59% of stake
    Traded Oct 27 Filed Oct 28
  3. Muna Bhanji Director
    Planned sale
    $81K 1,864 shares at $43.70 4.4% of stake
    Traded Oct 19 Filed Oct 20
  4. John Leite Global Chief Commercial Off
    Planned sale
    $161K 4,015 shares at $40.00 3.1% of stake
    Traded Sep 21 Filed Sep 22
  5. Jens Holstein Director
    Planned sale
    $205K 5,000 shares at $40.95 15% of stake
    Traded Sep 14 Filed Sep 16
  6. Annie McGuire EVP, General Counsel
    Planned sale
    $140K 3,254 shares at $43.09 2.4% of stake
    Traded Sep 4 Filed Sep 4
  7. Rebecca Chambers CFO
    Planned sale
    $157K 3,652 shares at $43.10 2.2% of stake
    Traded Sep 4 Filed Sep 4
  8. Phillip G. Febbo Chief Scientific & Med Officer
    Planned sale
    $564K 13,110 shares at $43.05 9% of stake
    Traded Sep 4 Filed Sep 4
  9. Muna Bhanji Director
    Planned sale
    $80K 1,864 shares at $42.97 4.2% of stake
    Traded Sep 1 Filed Sep 3
  10. Karin Eastham Director
    Planned sale
    $197K 3,729 shares at $52.89 20% of stake
    Traded Jun 18 Filed Jun 22
  11. John Leite Global Chief Commercial Off
    Planned sale
    $700K 13,975 shares at $50.07 9.6% of stake
    Traded Jun 4 Filed Jun 4
  12. Annie McGuire EVP, General Counsel
    Planned sale
    $158K 3,176 shares at $49.76 2.3% of stake
    Traded Jun 4 Filed Jun 4
  13. Rebecca Chambers CFO
    Planned sale
    $177K 3,561 shares at $49.73 2% of stake
    Traded Jun 4 Filed Jun 4
  14. Marc Stapley CEO
    Planned sale
    $6.9M 138,051 shares at $50.12 24% of stake
    Traded Jun 4 Filed Jun 4
  15. Jonathan Wygant VP, Chief Accounting Officer
    Sale
    $1.1M 24,000 shares at $45.40 35% of stake
    Traded May 22 Filed May 27

Also filed in the last 12 months, not counted as buying or selling: 30 share withholdings for taxes, 24 stock grants, and 7 option exercises.

Congress

1 member of Congress traded VCYT in the last three years: 3 buys and 1 sale. 2 members listed it in 2025 annual reports.

All Congress trades
  1. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Mar 3 filed Apr 7
  2. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Feb 18 filed Mar 9
  3. Gilbert Ray Cisneros, Jr. D-CA-31 Partial sale $1K–$15K Nov 12, 2025 filed Dec 15, 2025
  4. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Jun 16, 2025 filed Jul 10, 2025

SEC filings

Recent issuer filings from EDGAR, 10 shown.

Filed Form Detail Links
SCHEDULE 13G/A —
SCHEDULE 13G/A —
10-Q
8-K 2.02,8.01,9.01
8-K 1.01,2.01,7.01,9.01
10-Q
8-K 2.02,9.01
8-K 5.02,5.07
SCHEDULE 13G/A —
SCHEDULE 13G/A —

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $361.05M $445.76M $517.14M
Gross profit — $298.14M $362.53M
Gross margin * — 66.9% 70.1%
Net income -$74.4M $24.14M $66.35M
Net margin * -20.6% 5.4% 12.8%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $285.62M $372.27M $488.38M
Total non-current assets * $829.28M $927.77M $917.64M
Total assets $1.11B $1.3B $1.41B
Total current liabilities $61.24M $78.63M $59.94M
Total non-current liabilities * $9.56M $45.44M $36.51M
Total equity $1.04B $1.18B $1.31B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $44.22M $75.1M $136.31M
Cash from investing $15.11M -$56.28M -$9.21M
Cash from financing $2.84M $4.9M -$4.22M
Net change in cash $62.33M $23.3M $123.6M

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf